NOT extended AGO a darling of Wall way Cambrex Corp.

NOT extended AGO a darling of Wall way Cambrex Corp. saw its shares put under water by more than one-third as it dramatically slashed 2003 profit projections in the face of the los of a major contract biopharmaceutical manufacturing customer, a tentative legal reconciliation with Mylan Laboratories Inc., and competitive pricing hurrys
Cambrex calculate upons to take an after-tax charge of around $85 million, or 32 cent by share related to the pacification bringing 2003 earnings for share (EPS) to $1.05 to $125 However, level excluding the charge, forecasted EP of $137 to $157 falls far

...